New pill shows promise for Hard-to-Treat cancers in early trial
NCT ID NCT06568614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new oral drug called BG-89894 (SYH2039) in 29 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals were to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. The trial was terminated, so final results may be limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BG-89894 (SYH2039) tablet
What this could lead to
If this drug proves safe and shows early signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid tumors that have a specific genetic change (MTAP deletion).
What could go wrong
This is a very early (Phase 1) study with only 29 participants, so the drug may not work or may cause serious side effects. The trial was terminated, meaning results may be incomplete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC MTAP-DELETED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, 102218, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Cancer Research South Australia
Adelaide, South Australia, SA 5000, Australia
-
Columbia University Irving Medical Center
New York, New York, 10032-3725, United States
-
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, 510120, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Next Virginia
Fairfax, Virginia, 22031, United States
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
Baltimore, Maryland, 21287, United States
-
St Vincents Hospital
Fitzroy, Victoria, VIC 3065, Australia
-
The First Hospital of China Medical University Hunnan Branch
Shenyang, Liaoning, 110167, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China